Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lactic acidosis14.01.01.0020.000653%Not Available
Laryngeal oedema22.04.02.001; 10.01.05.003; 23.04.01.0050.000653%
Laryngospasm22.04.02.0020.000093%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000905%
Leukocytosis01.02.01.0020.000233%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Lichen planus23.03.08.001--Not Available
Lip oedema23.04.01.006; 10.01.05.004; 07.05.04.0040.001352%Not Available
Lip pain07.05.05.0290.000093%
Lip swelling07.05.04.005; 23.04.01.007; 10.01.05.0050.001539%Not Available
Lipoma16.18.01.001; 15.09.01.0010.000093%Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.002191%Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.002--Not Available
Lung disorder22.02.07.0010.000559%Not Available
Lung infiltration22.01.02.0040.000280%Not Available
Lymphadenopathy01.09.01.0020.000746%Not Available
Malaise08.01.01.0030.004196%
Malignant melanoma23.08.01.001; 16.03.01.0010.000466%Not Available
Marrow hyperplasia16.21.01.001; 01.13.01.0010.000186%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.000606%
Mental impairment19.21.02.003; 17.03.03.0020.000186%Not Available
Metabolic acidosis14.01.01.0030.000606%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000140%Not Available
Miosis17.02.11.002; 06.05.03.0030.000326%Not Available
Mitral valve incompetence02.07.01.0020.000186%Not Available
Monocytosis01.02.01.004--Not Available
Monoplegia17.01.04.0030.000140%Not Available
Mood altered19.04.02.0070.000485%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene